VivoSeq
Other

Immune

0

Pipeline Programs↗

15

Active Trials↗

9

Companies Involved↗

Immune is an early-stage landscape with 0 programs across 9 companies. The most active players are CSL Behring, Emergent BioSolutions, Ouro Medicines.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

CSL Behring logo

CSL Behring

0 programs

PreclinicalEmergent BioSolutions logo

Emergent BioSolutions

0 programs

PreclinicalO

Ouro Medicines

0 programs

PreclinicalS

Sigmoid Pharma

0 programs

PreclinicalA

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

0 programs

PreclinicalB

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

86

clinical trials

Completed52 · 60%
Unknown status13 · 15%
Recruiting7 · 8%
Not yet recruiting4 · 5%
Active, not recruiting4 · 5%
Withdrawn4 · 5%
Other2 · 2%

Clinical Trials

Trial Activity

86 trials

Immune Spatial Features of Guselkumab Cutaneous Response
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT05858632·10 enrolled
OM336 in Autoimmune Cytopenias
Recruiting·OOuro Medicines·Phase 1·NCT07083960·32 enrolled
Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT04005638·200 enrolled
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)
Recruiting·—·N/A·NCT06488118·36 enrolled
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
Recruiting·TThe Hospital for Sick Children·N/A·NCT04559425·350 enrolled
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT06387654·800 enrolled
A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease
Recruiting·SShandong First Medical University·Phase 1/2·NCT06900010·30 enrolled
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT03421288·677 enrolled
Immune Disorder HSCT Protocol
Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT01821781·20 enrolled
Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23
Active, not recruiting·BBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd·Phase 3·NCT06314867·990 enrolled
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Active, not recruiting·AAlpine Immune Sciences, Inc.·Phase 1/2·NCT05757570·30 enrolled
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Not yet recruiting·SSeismic Therapeutic AU Pty Ltd·Phase 1·NCT07455578·24 enrolled
Auto-immune Contribution in Symptom-based Sensory and Autonomic Disorders
Not yet recruiting·KKing's College London·N/A·NCT06992531·250 enrolled
Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
Not yet recruiting·WWeill Medical College of Cornell University·Phase 2·NCT07090174·27 enrolled
A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
Not yet recruiting·—·N/A·NCT07154914·396 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)